TABLE 2

Prevalence of Vaccine-Type HPV and Between-Wave Changes by Vaccination Status Adjusted for Propensity Score

Vaccination StatusPrevalence of HPV Types Across Waves, Propensity Score Adjusted, %Between-Wave Changes in HPV Prevalence, Propensity Score Adjusted, % (95% CI) [% Decline or Increase]
Wave 1, N = 371Wave 2, N = 409Wave 3, N = 400Wave 4, N = 400Wave 1–2Wave 2–3Wave 3–4Wave 1–4
Types in the 9-valent vaccinea
 All46.133.822.317.6−12.3 (−19.2 to −5.5) [−26.7]b−11.5 (−17.6 to −5.4) [−34]b−4.7 (−10.2 to 0.8) [−21.1]−28.5 (−34.8 to −22.2) [−61.8]b
 Vaccinated46.632.616.713.5−14 (−21.8 to −6.2) [−30]b−15.9 (−23.2 to −8.5) [−48.8]b−3.2 (−8.9 to 2.5) [−19.2]−33.1 (−39.4 to −26.8) [−71]b
 Unvaccinated43.435.045.542.1−8.3 (−17.3 to 0.6) [−19.4]+10.5 (−1.3 to 22.2) [30]−3.4 (−18.5 to 11.7) [−7.5]−1.3 (−14.3 to 11.8) [−3.0]
Types in the 4-valent vaccinec
 All34.613.58.28.6−21.1 (−27.0 to −15.3) [−61]b−5.3 (−9.6 to −1.0) [−39.3]b+0.5 (−3.4 to 4.3) [4.9]−26.0 (−31.6 to −20.4) [−75.1]b
 Vaccinated35.09.93.36.7−25.1 (−31.2 to −18.9) [−71.7]b−6.6 (−10.9 to −2.3) [−66.7]b+3.5 (+0.05 to 6.9) [103]b−28.2 (−33.8 to −22.7) [−80.9]b
 Unvaccinated32.41722.319.4−15.4 (−22.9 to −7.9) [−47.5]b+5.3 (−4.3 to 14.9) [31.2]−2.9 (−15.2 to 9.4) [−13]−13 (−23.8 to −2.2) [−40.1]b
Types in the 9-valent but not 4-valent vaccined
 All23.924.816.812.1+1.0 (−5.1 to +7.0) [3.8]−8.1 (−13.6 to −2.5) [−32.3]b−4.7 (−9.6 to 0.2) [−28]−11.8 (−17.2 to −6.4) [−48.1]b
 Vaccinated23.426.614.17.3+3.1 (−3.9 to +10.2) [13.7]−12.4 (−19.3 to −5.5) [−47]b−6.8 (−11.8 to −1.9) [−48.2]b−16.1 (−21.3 to −11.0) [−68.8]b
 Unvaccinated22.92430.436.1+1.1 (−6.7 to +9.0) [4.8]+6.4 (−4.4 to 17.1) [26.7]+5.8 (−8.7 to 20.2) [18.8]+13.2 (−0.8 to +25.7) [57.6]
  • CI, confidence interval.

  • a HPV-6, -11, -16, -18, -31, -33, -45, -52, and -58.

  • b P < .05.

  • c HPV-6, -11, -16, and -18.

  • d HPV-31, -33, -45, -52, and -58.